Open-label non-inferiority trial in 69 Japanese centres: 2,280 STEMI patients randomised to prasugrel monotherapy (20 mg loading, 3.75 mg daily, Japanese dosing) started before PCI, or 12 months of DAPT. Death, MI or stroke at 12 months 11.0 versus 8.5 percent (HR 1.34, 95% CI 1.02 to 1.75; non-inferiority not met); BARC 3 or 5 bleeding 5.6 versus 8.4 percent (HR 0.66). Presented by Gaku Nakazawa in Hot Line 3, NEJM.
